// App-Quantinova.ai

TPS6589 : Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Researchers

Presenter

  • Lillian L. Siu

Principal Investigators

  • Barbara Burtness

  • Ezra E.W. Cohen

  • Kevin Joseph Harrington

  • Lisa F. Licitra

  • Danny Rischin

  • Ying Zhu

  • Chooi Peng Lee

  • Cecilia Pinheiro

  • Ramona F. Swaby

  • Jean-Pascal H. Machiels

  • Makoto Tahara

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Yale School of Medicine, Smilow Cancer Center, New Haven, CT

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Institute of Cancer ResearchRoyal Marsden National Institute for Health Research Biomedical Research Centre, London, United Kingdom

  • Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Merck & Co., Inc., Kenilworth, NJ

  • Eisai, Hatfield, Hertfordshire, United Kingdom

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • National Cancer Center, EPOC, Chiba, Japan

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT04199104

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved